By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...